The Shift from Generic Reputation to CDMO Authority

Polpharma API had spent years building a strong reputation in the generics API space. When the business opened a CDMO division, it stepped into a different kind of competition. Most CDMOs lead with scale and technology. Few differentiate on the quality of the partnership experience — particularly for agile biotech companies that need a manufacturer who can move with them, not just process their batches.

The CDMO market is crowded with identical-sounding claims. Excellence, collaboration, end-to-end solutions — these words appear on every competitor’s website. What distinguishes one CDMO from another in the mind of a VP of R&D or a Head of CMC is not capability statements, but how clearly a partner demonstrates they understand the actual pressures of running a clinical-stage drug development programme.

Polpharma API had real differentiation: strong chemistry capabilities, dedicated project teams, regulatory-first thinking, and a genuine commitment to availability and communication. The challenge was translating that into a positioning and a content strategy that would make decision-makers in the US, Japan, and South Korea take notice.

‍

From Value Proposition to Growth Campaign in B2B Pharma

Clipatize was approached to do two things in sequence. First, develop a value proposition — built on workshops and strategic input from the Polpharma API team — that could credibly set the business apart in a market where technical specifications alone would not cut through. Second, design and execute an initial campaign that would test the positioning, identify what resonated with the target audience, and create the infrastructure — retargeting pools, algorithmic learning, content formats — needed to scale activity into a sustained, full-year programme.

The target audience was specific: VP R&D, Head of CMC, and Project Directors at biotech companies in clinical Phase I–III and preparing for commercial scale, across the US, Japan, and South Korea. The positioning idea that emerged from the strategy work was straightforward: Zero-Error Thinking. Powered by People.

LinkedIn Thought Leadership and Google Search for CDMO Marketing

Rather than opening with lead generation, the campaign was designed to earn credibility first and convert later. 

Phase 1 — Awareness of Differentiation focused on making the Polpharma API CDMO name known for the right reasons. LinkedIn Thought Leader Ads put real voices from across the business front and centre: each leader published editorial posts addressing specific pain points their clients face. A brand awareness document ad ran alongside Google Search to capture high-intent traffic from the start.

Phase 2 — Proof of Claims shifted the content toward evidence, keeping everything on-platform where engagement was already strong. LinkedIn Document Ads remained the primary format, this time built around social proof and concrete business arguments rather than brand positioning. 

Phase 3 — Lead Engagement deepened the relationship. A CDMO comparison guide positioned Polpharma API against industry standards. Thought Leader posts addressed late-stage decision-making concerns: regulatory timing or scale-up complexity.

The results: outperforming benchmarks across every metric

LinkedIn Document Ads delivered a CTR of 4.7% against an industry benchmark of 0.5–1.0%. Engagement rates reached 9%, compared to a benchmark of 1.8–6.0%. Thought Leader Ads performed even more distinctly: a CTR of 6.5% against a benchmark of 0.7–3.5%, and a dwell time of 9.54 seconds versus the 4–5 second benchmark.

The cost story was equally strong. US B2B Healthcare and Pharma is one of the more expensive segments for digital advertising. The campaign’s average cost-per-click came in well below the typical market rate — not by reducing spend, but because the content was genuinely more relevant and engaging to the audience being reached. When LinkedIn’s algorithm identifies high engagement, it rewards the advertiser with lower distribution costs.

On Google Search the strategy of bidding aggressively on high-intent CDMO keywords meant that users arriving from LinkedIn who then searched for CDMO services would find Polpharma API at the top of results, not a competitor.

What this campaign taught us about CDMO marketing

Format matters more than budget. Shifting from standard traffic ads to LinkedIn Document Ads and Thought Leader Ads meaningfully reduced costs while significantly increasing the time prospects spent engaging with the content.

Real voices outperform brand voice. The best-performing ad in the campaign was not a polished brand piece — it was a first-person post from a real Polpharma API employee addressing a real industry frustration. 

Start with proof, then scale. The value of this initial campaign was not just in the results it delivered — it was in the infrastructure it built. Retargeting pools, algorithm learning, and a validated content formula are assets that compound. The 3-month campaign gave Polpharma API exactly what it needed to move into a sustained, full-year digital programme with confidence.

What’s next

The initial campaign gave Polpharma API a validated content formula and a clear picture of what resonates with biotech decision-makers. The next phase expands coverage into EU markets.

For a CDMO trying to compete in a market dominated by larger, more recognised players, this campaign demonstrated that the right content reaching the right people at the right time can outperform on every metric that matters — and build the foundations for something much larger. That kind of result does not come from an agency working in isolation. It comes from a client who knows their business and a team willing to work closely enough to translate that knowledge into content that actually lands.